ClinicalTrials.gg
CompletedNCT07079618Updated Nov 25, 2025

A Research Study to Evaluate the Safety and Tolerability of SGC001 in Healthy Subjects

A Phase 1 interventional study of SGC001 and Placebo in Anterior Myocardial Infarction, sponsored by Beijing Sungen Biomedical Technology Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-25.

Sponsored by Beijing Sungen Biomedical Technology Co., Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2025, 1 year 4 months ago, and no results have been posted to the registry.
  • Registered 10 months after the study started (first participant enrolled Aug 2024, registered Jun 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

Acute Myocardial Infarction (AMI) is an acute ischemic necrosis that occurs following acute stenosis or occlusion of the coronary arteries, and it is associated with a high morbidity and mortality rate. Acute myocardial infarction typically occurs in middle-aged and elderly individuals, according to the American Heart Association, with the average age of first occurrence being 65.1 years for men and 72.0 years for women. Myocardial infarction (MI) has a significant impact on global health, affecting over 7 million people worldwide annually. In addition, MI can impose a substantial economic burden on society and families. The research study is a Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Phase Ia Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Pharmacodynamics Profile, and Immunogenicity of SGC001 in Healthy Adult Subjects

02

Conditions studied

  • Anterior Myocardial Infarction
03

In context

Anterior Wall Myocardial Infarction

36 studies on the registry are indexed under Anterior Wall Myocardial Infarction; 5 are open to participants now.

This study's enrollment of 49 is below the median of 110 across 28 interventional studies indexed under Anterior Wall Myocardial Infarction.

Browse Anterior Wall Myocardial Infarction studies →

Lead sponsor

Beijing Sungen Biomedical Technology Co., Ltd is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who fully understand the purpose, nature, method, and potential adverse reactions of the trial, and who voluntarily sign the form and agree to participate in the study.
  2. Healthy male or female subjects aged 18 \~ 50 years (both inclusive, based on the time of signing the informed consent form).
  3. (BMI): 19.0 \~ 26.0 kg/m2 (both inclusive), body weight of male subjects ≥50.0 kg, and body weight of female subjects ≥45.0 kg.
  4. Female subjects of must agree to use effective from screening until 3 months after receiving the drug. In addition, they must agree to refrain from collecting or donating eggs during this period; their male partner of childbearing potential must also agree to use effective contraception during this period.
  5. Male subjects of childbearing potential must agree to use effective contraception and have no plans to conceive or donate sperm from screening until 3 months after receiving the investigational drug. During this period, their female partner of childbearing potential must also agree to use effective contraception.

Exclusion criteria

Exclusion Criteria:

  1. Individuals with known allergy to therapeutic protein drugs or food or who may be allergic to the test drug or any component of the drug, based on the investigator's judgment.
  2. Individuals with a history of cardiovascular disease.
  3. Individuals with a history of acute or chronic bronchospasm, including treated or untreated asthma, and (COPD).
  4. Individuals with a history of disease.
  5. Individuals with a history of malignant tumors.
  6. Individuals with abnormalities on physical examination, vital signs examination, or laboratory tests, as judged by the clinician.
  7. Individuals with a history of drug abuse within the past 5 years, the presence of drug abuse within 3 months before the study, or a positive drug abuse screening result.
  8. Individuals who have smoked within 3 months before screening (consuming ≥ 5 cigarettes per day) or habitual use of nicotine containing products.
  9. Individuals who have consumed more than 14 units of alcohol per week (1 unit of alcohol = 360 mL of beer or 45 mL of spirits with 40% of alcohol content or 150 mL of wine) within 3 months prior to screening, or who consume alcohol-containing products within 48 hours before dosing, or who have a positive alcohol breath test result at screening and/or D-1.
  10. Individuals who have received monoclonal antibody or biologic therapy within 3 months prior to receiving the investigational drug.
  11. Individuals who have received medications that may affect the immune system (e.g., , cytokines and cytokine inducers,) within 3 months prior to receiving the investigational drug.
  12. Individuals who have received anticoagulant or antiplatelet medications within 28 days prior to receiving the investigational drug.
  13. Individuals who have received any vaccine within 28 days prior to receiving the investigational drug, or who plan to receive a vaccine during the trial period.
  14. Individuals who have suffered from clinically significant major diseases or undergone major surgical procedures within 28 days prior to receiving the investigational drug, or who anticipate requiring major surgery during the trial period.
  15. Individuals who have used any prescription drugs, over-the-counter drugs, Chinese herbal medicines, or health supplements within 14 days prior to receiving the investigational drug or within the 5 half-lives of the drug (whichever is longer).
  16. Individuals whose screening viral serology tests are positive for antigen/antibodies (HIV-Ag/Ab), surface antigen (HBsAg), virus antibodies (HCV-Ab), or antibodies to Treponema pallidum (TP-Ab).
  17. Individuals who have difficulty in venous blood collection or have a history of needle and blood fainting.
  18. Women who have positive result in pregnancy test or are breastfeeding at Screening or D-1.
  19. Individuals who have participated in other drug clinical studies and received other clinical trial drugs within 3 months prior to receiving the investigational drug.
  20. Individuals who have history of blood donation or massive blood loss (≥ 400 mL) within 3 months prior to screening.
  21. Any other circumstance that, in the judgement of the investigator, may affect the ability of the subject to provide or to follow the trial protocol, or where the subject's participation in the trial may affect the outcome of the trial or his/her safety.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    SGC001

    Administration should be initiated as early as possible, with a single intravenous injection completed within 6 hours of disease onset.

    Drug: SGC001

  • Placebo comparator
    Placebo

    Administration should be initiated as early as possible, with a single intravenous injection completed within 6 hours of disease onset.

    Drug: Placebo

Interventions

  • DrugSGC001

    In this study, 6 dose groups are planned. 8 subjects are enrolled in each group. A total of 48 subjects will be enrolled. The administration method for each group is as follows: The drug SGC001 should be administered once via intravenous injection within 6 hours and the administration time 10 minutes.

  • DrugPlacebo

    In this study, 6 dose groups are planned. 8 subjects are enrolled in each group. A total of 48 subjects will be enrolled. The administration method for each group is as follows: The drug placebo should be administered once via intravenous injection within 6 hours and the administration time 10 minutes.

06

What researchers measure

Primary outcomes

  1. Adverse events (AEs)

    Adverse events (AEs)

    Time frame: From randomisation to end-of-study (up to 57 days)

  2. Serious adverse events (SAEs)

    Serious adverse events (SAEs)

    Time frame: From randomisation to end-of-study (up to 57 days)

  3. ECG QT Interval

    ECG QT Interval

    Time frame: From randomisation to end-of-study (up to 57 days)

  4. Number of participants with Laboratory tests

    hematology, blood chemistry, urinalysis, and coagulation

    Time frame: From randomisation to end-of-study (up to 57 days)

Secondary outcomes

  1. Maximum Concentration (Cmax)

    Maximum Concentration (Cmax)

    Time frame: Day 1-Day 4, Day 6, Day 8-Day 57

  2. Time to maximum concentration (Tmax)

    time to maximum concentration (Tmax)

    Time frame: Day 1-Day 4, Day 6, Day 8-Day 57

  3. Area under the plasma concentration-time curve from time 0 to the last quantifiable time point postdose (AUC0-t)

    Area under the plasma concentration-time curve from time 0 to the last quantifiable time point postdose (AUC0-t)

    Time frame: Day 1-Day 4, Day 6, Day 8-Day 57

  4. Area under the plasma concentration-time curve from time zero to infinity (AUC0-inf)

    Area under the plasma concentration-time curve from time zero to infinity (AUC0-inf)

    Time frame: Day 1-Day 4, Day 6, Day 8-Day 57

  5. Elimination half-life (t1/2)

    Elimination half-life (t1/2)

    Time frame: Day 1-Day 4, Day 6, Day 8-Day 57

  6. Elimination rate constant (λz)

    Elimination rate constant (λz)

    Time frame: Day 1-Day 4, Day 6, Day 8-Day 57

  7. Interleukin-6(IL-6) [PD endpoints]

    Interleukin-6(IL-6)

    Time frame: Day 1-Day 2,Day 4,Day 8-Day 22

  8. Tumor necrosis factor-α(TNF-α)[PD endpoints]

    Tumor necrosis factor-α(TNF-α)

    Time frame: Day 1-Day 2,Day 4,Day 8-Day 22

  9. Immunoglobulin G (IgG)[PD endpoints]

    Immunoglobulin G (IgG)

    Time frame: Day 1-Day 2,Day 4,Day 8-Day 22

  10. Interleukin-1 β (IL-1 β)[PD endpoints]

    Interleukin-1 β (IL-1 β)

    Time frame: Day 1-Day 2,Day 4,Day 8-Day 22

  11. Qualitative detection of anti-drug antibodies in serum(Anti-drug antibody (ADA))

    Qualitative detection of anti-drug antibodies in serum, followed by calculation of the positivity rate as the number of positive samples divided by the total number of samples

    Time frame: Day 1,Day 8-Day 15,Day 29-Day 57

07

Study locations

1 site
  • Beijing Anzhen Hospital Capital Medical University
    Beijing, Beijing Municipality 100013, China
08

References and documents

Individual participant data

Plan to share: No — The individual participant data(IPD) will be shared if necessary

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2024 to primary completion in Jul 2025, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2025
First posted
Jul 23, 2025
StartActual
Aug 20, 2024
Primary completionActual
Jul 15, 2025
CompletionActual
Jul 15, 2025
Last update
Nov 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07079618
Lead sponsor
Beijing Sungen Biomedical Technology Co., Ltd
Responsible party
Sponsor
First posted
Jul 23, 2025
Start date
Aug 20, 2024
Primary completion
Jul 15, 2025
Completion
Jul 15, 2025
Last update
Nov 25, 2025

Study contacts

Yang Lin, Ph.D
principal investigator · Beijing Anzhen Hospital

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SGC001

Start the discussion